No trading implication from this filing; standard equity grants for new hires. Monitor for larger personnel moves or clinical updates as potential catalysts.
Price Chart
Executive Summary
Iovance Biotherapeutics granted inducement stock options covering 135,470 shares to twelve new non-executive employees, priced at $3.80 per share with three-year vesting. This is a routine hiring incentive and does not reflect a material strategic or financial change.
Key Facts
- Iovance granted stock options for 135,470 shares to twelve new non-executive employees.
- Options were granted under the 2021 Inducement Plan, compliant with Nasdaq Rule 5635(c)(4).
- Exercise price is $3.80, equal to the closing price on the grant date (April 16, 2026).
- Vesting: one-third on first anniversary, remainder over eight quarterly installments thereafter.
- No executive-level hires or material financial terms disclosed.
Financial Impact
Minimal near-term financial impact; dilution from 135,470 shares (~0.03% of 440M outstanding shares, based on $1.6B market cap).
Risk Factors
- Minor dilution over time as options vest.
- No performance conditions tied to vesting, though standard for inducement grants.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276514 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 21, 2026 5w ago | Press Release | $8.06 $10.64 | ▲ +32.01% | ▲ +30.70% | $14.24 (+76.67%) |
Aug 6, 2026 8w ago | 8-K | $6.34 $8.79 | ▲ +38.64% | ▲ +39.04% | $14.24 (+124.61%) |
Aug 6, 2026 8w ago | 8-K | $6.21 $8.70 | ▲ +40.10% | ▲ +39.50% | $14.24 (+129.31%) |
Jul 16, 2026 11w ago | Court Ruling | $4.66 $6.52 | ▼ −39.91% | ▼ −36.30% | $14.24 (−205.58%) |
Jul 2, 2026 13w ago | 8-K | $4.31 $4.69 | ▲ +8.82% | ▲ +9.23% | $14.24 (+230.39%) |
Jun 19, 2026 14w ago | Press Release | $4.06 $5.00 | ▲ +23.15% | ▲ +23.30% | $14.24 (+250.74%) |
Jun 18, 2026 15w ago | S-3ASR | $4.06 $5.00 | ▲ +23.15% | ▲ +23.30% | $14.24 (+250.74%) |
Jun 10, 2026 16w ago | 8-K | $3.96 $4.37 | ▲ +10.35% | ▲ +8.46% | $14.24 (+259.60%) |
May 22, 2026 18w ago | Press Release | $4.10 $4.34 | ▲ +5.87% | ▲ +7.81% | $14.24 (+247.32%) |
Apr 28, 2026 22w ago | DEFA14A | $3.31 $4.30 | ▲ +29.91% | ▲ +23.86% | $14.24 (+330.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access